Global Antisense and RNAi Therapeutics Market Size (2024 - 2029)

The antisense and RNAi therapeutics market is poised for growth, driven by advancements in therapeutic outcomes for rare diseases and increased research funding. The market's expansion is supported by the development of gene silencing technologies, which offer targeted treatment options for conditions like spinal muscular atrophy and acute hepatic porphyria. Despite setbacks during the COVID-19 pandemic, which disrupted healthcare services and reduced demand, the market is expected to recover due to a strong pipeline of promising products and ongoing R&D activities. The limited treatment options for rare diseases further fuel the demand for innovative therapies, contributing to the market's growth trajectory.

Market Size of Global Antisense and RNAi Therapeutics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Antisense and RNAi Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 7.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

Antisense and RNAi Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Antisense & RNAi Therapeutics Market Analysis

The antisense and RNAi therapeutics market is expected to register a CAGR of 7.1% over the forecast period, 2022-2027.

The COVID-19 pandemic led to seriously deleterious effects on public health systems in many countries. For instance, the healthcare industry was burdened with pandemic crisis management. Furthermore, worldwide lockdowns were imposed to curb the viral outbreak. This in turn led to a shortage of healthcare staff across the globe. Similarly, the pharmaceuticals' manufacturing activities and supply chain worldwide. were also obstructed. In addition, the Antisense and RNAi therapeutics market also suffered substantial losses during the COVID-19 pandemic. There was a sharp decline in the outpatient services offered in hospitals and clinics during the pandemic. Thus, patients receiving treatment for rare genetic conditions such as spinal muscular atrophy (SMA), acute hepatic porphyria, Duchenne muscular dystrophy (DMD), and others experienced delayed drug infusion or disruptions in drug infusion services provided by the healthcare staff. Hence, this leads to a decrease in demand for antisense and RNAi therapeutics. For instance, according to a survey finding released by National Organization for Rare Disorders, Inc. (NORD) in May 2020 in the United States, 74% of patients suffering from rare diseases had a medical appointment canceled. Similarly, according to a survey conducted by the Rare Diseases Clinical Research Network (RDCRN) in the year 2020, only a few patients suffering from rare diseases were able to get an appointment with a medical provider. Thus, the decline in hospital visits during the pandemic impacted the growth of the studied market.

The major factor that leads to the growth of the studied market includes better therapeutic outcomes for rare diseases with the use of antisense and RNAi therapeutics. Furthermore, other factors such as the surge in R&D funding coupled with the presence of promising pipeline products also drive the growth of the market.

RNAi therapeutics are based on a technology that works by preventing cells from producing a specific protein that contributes to disease. Furthermore, this technology is also called gene silencing technology. Some of these rare diseases include spinal muscular atrophy, heterozygous familial hypercholesterolemia (HeFH), acute hepatic porphyria, and others. Hence, this technique has improved the treatment options for rare diseases. For instance, the siRNA therapies identify and bind to the disease-causing mRNA leading to its destruction. Hence, this renders RNAi therapeutics as highly target specific and selective making them a preferred and advanced treatment option for rare diseases. Thus, this leads to a surge in demand for RNAi therapeutics, thereby driving the growth of the market.

In addition, the treatment options available for rare disease across the world is limited. Hence, there has been a gradual increase in the funding related to research activities associated with the discovery of new therapies for rare diseases. For instance, in January 2022, the Food and Drug Administration Office of Orphan Products Development (OOPD) announced the availability of funds to support studies for rare diseases and conditions. In addition, these studies are also expected to provide data to the FDA contributing to the approval of new products, or new indications for already marketed products. Hence, this is expected to lead to a surge in R&D activities related to antisense and RNAi therapeutics for rare diseases. Furthermore, the presence of strong pipeline products which are expected to be launched during the forecast period also drives the growth of the market. For instance, AB-729 is an RNAi therapeutic candidate which is currently being studied by Arbutus Biopharma. Furthermore, AB-729 is in Phase II of clinical trials and is being studied for its therapeutic action in Hepatitis B patients. Similarly, ISTH0036 is another RNAi therapeutic being studied by Isarna Therapeutics GmbH. The drug candidate is present in phase II of clinical trials and is being studied for diabetic macular edema. In addition, GS-101 (Aganirsen) is an antisense oligonucleotide studied by Gene Signal International SA. The drug candidate is currently in phase III of a clinical trial for keratoplasty rejection. Thus, these drug candidates are expected to hit the market in near future. Furthermore, this is expected to lead to a surge in demand for this novel RNAi and antisense therapeutics thereby driving the growth of the market.

Antisense & RNAi Therapeutics Industry Segmentation

As per the scope of the report, antisense and RNAi therapeutics are defined as medications that work by turning off the production of specific genes which are responsible for diseases or medical conditions in the body. The antisense and RNAi therapeutics market is segmented by Therapeutics (RNA Interference and RNA Antisense), Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others), Indication (Autosomal Recessive Disease, Autosomal Dominant Disease, Chromosomal Disease, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Therapeutics
RNA Interference
RNA Antisense
By Route of Administration
Intravenous Route
Subcutaneous Route
Intrathecal Route
Pulmonary Delivery
Intraperitoneal Injection
Others
By Indication
Autosomal Recessive Disease
Autosomal Dominant Disease
Chromosomal Disease
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Antisense and RNAi Therapeutics Market Size Summary

The antisense and RNAi therapeutics market is poised for significant growth, driven by advancements in gene silencing technologies that offer improved therapeutic outcomes for rare diseases. These therapies, which include RNA interference (RNAi) and antisense oligonucleotides, have become pivotal in treating conditions such as spinal muscular atrophy, Duchenne muscular dystrophy, and acute hepatic porphyria. The market's expansion is supported by increased research and development funding, alongside a robust pipeline of promising products. Despite the challenges posed by the COVID-19 pandemic, which disrupted healthcare services and led to a temporary decline in demand, the market is recovering as awareness and demand for these advanced treatment options rise. The limited availability of treatment options for rare diseases has further fueled interest and investment in this sector.

North America is expected to lead the market, benefiting from a well-established healthcare infrastructure and early screening programs that enhance the demand for antisense and RNAi therapeutics. The region's dominance is also attributed to the presence of major pharmaceutical companies and the availability of advanced therapeutic products. The market is characterized by a consolidated landscape with key players such as Alnylam Pharmaceuticals, Biogen Inc., and Sarepta Therapeutics, among others, driving innovation and product development. Recent regulatory approvals and strategic collaborations, such as those involving Novartis AG and AstraZeneca plc, are anticipated to further propel market growth. As these companies continue to advance their therapeutic candidates through clinical trials, the market is expected to witness a surge in demand for novel RNAi and antisense therapeutics, reinforcing its growth trajectory.

Explore More

Global Antisense and RNAi Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Better Therapeutic Outcomes for Rare Disease Due to Effective Gene Slicing Technology

      2. 1.2.2 Surge in R&D funding Coupled with Presence of Promising Pipeline Products

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Therapeutics

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Therapeutics

      1. 2.1.1 RNA Interference

      2. 2.1.2 RNA Antisense

    2. 2.2 By Route of Administration

      1. 2.2.1 Intravenous Route

      2. 2.2.2 Subcutaneous Route

      3. 2.2.3 Intrathecal Route

      4. 2.2.4 Pulmonary Delivery

      5. 2.2.5 Intraperitoneal Injection

      6. 2.2.6 Others

    3. 2.3 By Indication

      1. 2.3.1 Autosomal Recessive Disease

      2. 2.3.2 Autosomal Dominant Disease

      3. 2.3.3 Chromosomal Disease

      4. 2.3.4 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Antisense and RNAi Therapeutics Market Size FAQs

The Global Antisense and RNAi Therapeutics Market is projected to register a CAGR of 7.10% during the forecast period (2024-2029)

Alnylam Pharmaceuticals, Inc., Biogen Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Sarepta Therapeutics, Inc. and Novartis AG are the major companies operating in the Global Antisense and RNAi Therapeutics Market.

Antisense & RNAi Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)